SCHEMBL17508104

SCHEMBL17508104

CC(N)CCN(CCCN)Cc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.45
PRMT6 Q96LA8 1/20 0.45
PRMT8 Q9NR22 1/20 0.45
SLC6A2 P23975 2/20 0.42
TAAR1 Q96RJ0 2/20 0.42
MAOA P21397 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
CYP2A6 P11509 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
HTR2A P28223 1/20 0.41
HRH1 P35367 1/20 0.41
DPP7 Q9UHL4 2/20 0.40
DPP8 Q6V1X1 1/20 0.40
DPP9 Q86TI2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8641400 0.90 BCHE (0.47) SLC6A2TAAR1MAOASLC6A4SLC6A3
SCHEMBL8850871 0.90 BCHE (0.47) SLC6A2TAAR1MAOASLC6A4SLC6A3
SCHEMBL713789 0.85 CARM1 (0.53) CARM1PRMT6PRMT8MAOA
SCHEMBL25221689 0.83 CARM1 (0.52) CARM1PRMT6PRMT8MAOA
SCHEMBL713894 0.81 CARM1 (0.50) CARM1PRMT6PRMT8MAOA
SCHEMBL17527074 0.81 MAOA (0.52) CARM1PRMT6PRMT8MAOA
SCHEMBL20989945 0.81 CARM1 (0.55) CARM1PRMT6PRMT8MAOA
SCHEMBL8027241 0.81 HDAC3 (0.50) CARM1PRMT6PRMT8MAOA
SCHEMBL1685452 0.81 CARM1 (0.53) CARM1PRMT6PRMT8MAOA
SCHEMBL22771183 0.80 BCHE (0.55) CARM1PRMT6PRMT8SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11639335-B2 Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2023-05-02 US disclosed
US-20220064118-A1 Asymmetric Bisaminoquinolines And Bisaminoquinolines With Varied Linkers As Autophagy Inhibitors For Cancer And Other Therapy NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-03 US disclosed
EP-3848355-A1 ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY The Trustees Of The University Of Pennsylvania (US) 2021-07-14 EP disclosed
US-11001558-B2 Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2021-05-11 US disclosed
EP-3177595-B1 ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY UNIV PENNSYLVANIA (US) 2021-02-24 EP disclosed
US-20190248747-A1 ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2019-08-15 US disclosed
US-10221140-B2 Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2019-03-05 US disclosed
US-20170275252-A1 ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2017-09-28 US disclosed
EP-3177595-A1 ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY The Trustees Of The University Of Pennsylvania (US) 2017-06-14 EP disclosed
WO-2016022956-A1 ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639335-B2 Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy SQSTM1, ATG7, BECN1 CARM1 436/4885PRMT6 1057/4885PRMT8 1180/4885
US-11001558-B2 Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy SQSTM1, ATG7, BECN1 CARM1 436/4885PRMT6 1057/4885PRMT8 1180/4885
US-20220064118-A1 Asymmetric Bisaminoquinolines And Bisaminoquinolines With Varied Linkers As Autophagy Inhibitors For Cancer And Other Therapy SQSTM1, ATG7, BECN1 CARM1 436/4885PRMT6 1057/4885PRMT8 1180/4885
US-20190248747-A1 ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY SQSTM1, ATG7, BECN1 CARM1 436/4885PRMT6 1057/4885PRMT8 1180/4885
US-20170275252-A1 ASYMMETRIC BISAMINOQUINOLINES AND BISAMINOQUINOLINES WITH VARIED LINKERS AS AUTOPHAGY INHIBITORS FOR CANCER AND OTHER THERAPY SQSTM1, ATG7, BECN1 CARM1 436/4885PRMT6 1057/4885PRMT8 1180/4885
US-10221140-B2 Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy SQSTM1, ATG7, BECN1 CARM1 436/4885PRMT6 1057/4885PRMT8 1180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.